CHALLENGES FOR GENERIC DRUG PRODUCERS

In the fiercely competitive global market for generic drugs, the complexities and interconnectivities come to the fore when a drug is recalled. In recent months, as you may be aware, the sartans (also known as AT1 receptor antagonists, angiotensin II receptor blockers/antagonists) have come into the limelight due to the recall of some of them from the regulated markets of USA and Europe.